Please try another search
For the three months ended 31 March 2013, Unigene Laboratories Inc revenues decreased 65% to $614K. Net income totaled $2M vs. loss of $3.2M. Revenues reflect Product Sales. decrease from $646K to $0K, Tarsa revenue decrease of 81% to $63K, Product Royalties decrease of 76% to $85K. Net Income reflects Change in fair value of embedded derivat increase from $2.9M to $11.9M (income).
Period Ending: | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 |
---|---|---|---|---|
Total Revenue | 0.61 | 1.54 | 3.41 | 29242.23 |
Gross Profit | -1.02 | 1.43 | 2.58 | 19057.29 |
Operating Income | -5.36 | -3.04 | -1.69 | 15256.48 |
Net Income | 1.98 | -15.34 | -4.5 | 13281.46 |
Period Ending: | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 |
---|---|---|---|---|
Total Assets | 5.35 | 11.31 | 13.21 | 407428.73 |
Total Liabilities | 101.84 | 110.05 | 96.78 | 217312.46 |
Total Equity | -96.49 | -98.74 | -83.57 | 190116.27 |
Period Ending: | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -3.41 | -3.18 | -3.12 | 28779.58 |
Cash From Investing Activities | -0.04 | -1.09 | -0.97 | -45693.43 |
Cash From Financing Activities | -0.01 | 3.4 | 3.41 | 45397.65 |
Net Change in Cash | -3.46 | -0.87 | -0.68 | 28483.81 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review